Sponsored by:

Molecular Imaging

ITM launches new oncology therapeutics division
By AuntMinnie.com staff writers
Lumara Bio will focus resources toward commercial readiness for ITM's lead drug candidate, lutetium-177 (Lu-177) edotreotide (ITM-11).
July 27, 2026
Lumara
Vanderbilt Health, Siemens enter partnership valued at $87 million
By AuntMinnie.com staff writers
Siemens Healthineers will supply MRI, CT, molecular imaging, interventional radiology, and radiation oncology systems for Vanderbilt Health locations.
July 27, 2026
Acquisitions
Curium reintroduces Tl-201 in the U.S.
By AuntMinnie.com staff writers
Production of the radiopharmaceutical had ceased in 2022.
July 27, 2026
Nuclear Medicine
SPECT/CT viable over PET/CT for high-risk prostate cancer staging
By Will Morton
Considering its broader accessibility, Tc-99m MIP-1404 CZT SPECT/CT may represent a practical alternative for primary staging.
July 24, 2026
Maximum intensity projection of Ga-68 PSMA-11 PET/CE-CT (A), Tc-99m MIP-1404 CZT SPECT/CT (B) and Tc-99m HDP CZT SPECT/CT (C) imaging. Ga-68 PSMA-11 PET/CE-CT and Tc-99m MIP-1404 CZT SPECT/CT showing tracer uptake in lymph nodes below the iliac bifurcation and above, paraaortic and left supraclavicular, bone uptake in the right proximal femur and right scapula (arrows). Tc-99m HDP CZT SPECT/CT did not show any uptake suspicious for metastatic disease. No sclerotic lesions suspicious of metastases were detected by the CT component in any of the studies. Fusion axial imaging of Ga-68 PSMA-11 PET/CE-CT (D) and Tc-99m MIP-1404 CZT SPECT/CT (E) showing uptake in lymph nodes in the left pelvic area below the iliac bifurcation (arrows). Fusion axial imaging of Ga-68 PSMA-11 PET/CE-CT (F) and Tc-99m MIP-1404 CZT SPECT/CT (G) showing uptake in the right proximal femur, not detected by Tc-99m HDP CZT SPECT/CT (H), (arrows).
Lutetium-177 PSMA-617 shows promise in earlier-stage prostate cancer
By Will Morton
Across 14 studies, PSA50 response rates (the number of patients with at least a 50% drop in PSA) ranged from 44% to 100%.
July 21, 2026
Prostate Imaging
GE HealthCare introduces MIM Anyware remote access platform
By AuntMinnie.com staff writers
The platform allows authorized users to access MIM software applications from any location without local installation.
July 21, 2026
Ge Health Care Logo New March 2023
Spectrum Dynamics expands Veriton SPECT/CT line
By AuntMinnie.com staff writers
The company has unveiled an all-energy enhancement for its CT-400 series digital SPECT/CT scanner.
July 20, 2026
Veriton CT 400 Series digital SPECT/CT scanner with all-energy enhancement.
Tau PET tracer flags early Alzheimer risk in healthy older adults
By Will Morton
Few studies have investigated how F-18 PI-2620 is associated with memory performance or AD-related biomarkers in cognitively unimpaired older adults.
July 17, 2026
F-18 PI-2620 average binding potential maps. Mean tracer binding (DVR) image from 165 older adults (A) and 13 young adults (B). Images are scaled from 1 to 1.8 for display purposes, but DVR values of less than 1 were frequently observed.
Varian highlights Fast-02 proton Flash therapy trial results
By AuntMinnie.com staff writers
Most participants reported complete pain relief at three months and with no adverse events from treatment.
July 16, 2026
(From left to right) Researchers Emily Daugherty, MD, Anthony Mascia, PhD, and John Perentesis, MD, inside the proton therapy treatment room at the Cincinnati Children's/University of Cincinnati Medical Center Proton Therapy Center.
AdvanCell raises $315M for targeted alpha therapy
By AuntMinnie.com staff writers
The company is developing ADVC001, a lead-212 (Pb-212)-based targeted alpha therapy for metastatic prostate cancer.
July 15, 2026
Cash Bills
Brain PET scans reveal neuron loss in long COVID
By Will Morton
The findings suggest that treatments aimed at boosting dopamine release could be repurposed to treat long COVID.
July 14, 2026
Representative participant from each group shown. C-11 DTBZ non-displaceable binding potential (BPND) in voxels quantitated with simplified reference tissue model 2. Color scale indicates C-11 DTBZ BPND from 0 (black) to 3.5 (red), with reduced C-11 DTBZ BPND observed in the long COVID case compared to both healthy controls.
Nucs AI, Segmed to build AI validation platform for theranostics
By AuntMinnie.com staff writers
The companies will develop disease-specific registries, curated research cohorts, and validation frameworks.
July 14, 2026
Artificial Intelligence Ai 400
Page 1 of 632
Next Page